May 10, 2022

Controversies and Current Issues in Spinal Cord Tumors

12 minutes

Ask the Experts: A Lifelong Learning Series - October 2021

Matt Goodwin, MD

Joseph Schwab, MD

Daniel Sciubba, MD

Disclosures:

Goodwin, Matthew L.: Consulting: Augmedics (A, Outside 12-Month Requirement), JBJS Classroom (A); Fellowship Support: AOSpine (Salary), NREF (Salary); Royalties: Kendall Hunt (B); Stock Ownership: ROM3 (200 Shares, Outside 12-Month Requirement, Paid directly to institution/employer).

Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AOSpine (Travel Expense Reimbursement, Outside 24-Month Requirement).

Sciubba, Daniel M.: Consulting: Baxter (B), DePuy Synthes (B), Medtronic (D), Stryker (C).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

...more

View all episodes

By North American Spine Society

4.4

1111 ratings

May 10, 2022

Controversies and Current Issues in Spinal Cord Tumors

12 minutes

Ask the Experts: A Lifelong Learning Series - October 2021

Controversies and Current Issues in Spinal Cord Tumors

Matt Goodwin, MD

Joseph Schwab, MD

Daniel Sciubba, MD

Disclosures:

Schwab, Joseph H.: Scientific Advisory Board: Chordoma Foundation (Nonfinancial); Speaking and/or Teaching Arrangements: AOSpine (Travel Expense Reimbursement, Outside 24-Month Requirement).

Sciubba, Daniel M.: Consulting: Baxter (B), DePuy Synthes (B), Medtronic (D), Stryker (C).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

...more